Sanliurfa Merkez

Researchers are investigating the frequency of Neuronal Ceroid Lipofusinosis Type 2 CLN2 in children aged 2 to 6 years who have nonspecific neurological symptoms such as idiopathic seizures, speech disorders, and motor dysfunctions. This multicenter, non-drug screening study focuses on children without hypoxic ischemic encephalopathy, head trauma, or developmental brain anomalies, aiming to better understand the demographic and clinical features of those with possible CLN2 disease. Children first undergo assessments including recording demographic and medical history, seizure frequency, cognitive and language development evaluations, physical exams assessing muscle strength, gait, and coordination, as well as neurological evaluations using EEG and MRI scans. Those showing specific signs like speech disorder with seizures, movement problems, particular EEG responses, or MRI findings will have blood samples taken to measure Tripeptidyl Peptidase 1 enzyme levels. If enzyme activity is low, genetic testing is performed to investigate CLN2 disease. Participants are involved for up to one year during which various clinical, neurological, and imaging evaluations are done. Blood samples are collected for enzyme and genetic analyses. The main outcome measured is the frequency of CLN2 disease in this group. The study tracks each childs symptoms, neurological findings, and imaging results to better identify and understand CLN2 in children with these symptoms.

Researchers are evaluating the combination of baxdrostat and dapagliflozin in people with chronic kidney disease CKD and high blood pressure hypertension. This Phase III, double-blind, placebo-controlled study aims to assess whether this combination reduces the risk of serious kidney damage, heart failure events, or cardiovascular death compared to dapagliflozin alone. The study includes participants with CKD and hypertension who meet specific kidney function and blood pressure criteria. Participants who are not already taking SGLT2 inhibitors will first complete a 4-week dapagliflozin run-in period. Then, they will be randomly assigned to receive either baxdrostat plus dapagliflozin or a placebo plus dapagliflozin. Baxdrostat dosing may start low and be increased if needed. Study visits will occur at 2, 4, 8, 16, 34, and 52 weeks after randomization, and then approximately every four months until the study ends, which is based on the number of key kidney or heart-related events. Throughout the study, participants will have regular assessments including blood tests to monitor kidney function and potassium levels, blood pressure measurements, and evaluations of heart and kidney health. If participants stop the blinded study drug early, they will continue dapagliflozin if possible and remain in the study for ongoing visits and monitoring. The main outcome is whether the combination treatment reduces the risk of a 50% sustained decline in kidney function, kidney failure, heart failure events, or cardiovascular death over up to 37 months.

Researchers are evaluating the safety and effectiveness of several long-acting antibody treatments for adults with moderately to severely active ulcerative colitis UC. This Phase 2, multicenter platform study aims to compare multiple investigational therapies, including both single agents and combinations, to better understand their potential benefits and risks. The study is sponsored by Spyre Therapeutics, Inc. and involves adults aged 18 to 75 years with active UC confirmed by endoscopy and histology.

Researchers are conducting a phase 2, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of SAR441566 in adults with moderate to severe Crohns Disease CD. The main goal is to compare different doses of SAR441566 against placebo in these participants. The study is sponsored by Sanofi and aims to understand how well SAR441566 works in treating CD. Participants will be randomly assigned to receive one of three different doses of SAR441566 or a matching placebo. The treatment is given orally as tablets. The study lasts up to 59 weeks, including a 4-week screening period, followed by a 52-week main treatment phase. This main phase has a 12-week double-blind induction period and a 40-week maintenance period. Eligible participants may also enter an open-label extension lasting up to 40 weeks, but the combined duration of the maintenance and open-label periods cannot exceed 40 weeks. Throughout the study, participants will visit regularly for assessments including endoscopy, stool frequency and abdominal pain scoring, and blood tests to measure drug levels and safety. Researchers will measure outcomes such as endoscopic response at week 12 and clinical remission using various indices. Safety will be monitored by tracking adverse events up to week 52. After treatment, a 2-week follow-up occurs for those not continuing in the long-term safety study, with total participant involvement lasting up to 59 weeks.

Researchers are studying felzartamab in adults with Immunoglobulin A nephropathy IgAN, a kidney disease caused by abnormal IgA antibodies building up in the kidneys leading to inflammation and damage. This Phase 3 clinical trial aims to understand how felzartamab affects proteinuria, the presence of protein in urine, and kidney function in people with IgAN. The safety and how the body processes felzartamab are also being evaluated. Participants will be randomly assigned to receive either felzartamab or a placebo through intravenous infusions during a 24-week treatment period. Some participants with lower kidney filtration rates will be grouped separately but also receive either felzartamab or placebo. After treatment, participants will enter an 80-week follow-up phase. In total, participants will have 17 study visits over about two years. Throughout the study, participants will have urine tests to measure proteinuria, blood tests to assess kidney filtration function, and monitoring for side effects. Researchers will also study felzartamab levels in the blood and check for immune reactions against the drug. Safety will be closely monitored using vital signs, laboratory tests, and physical exams during the entire 104-week period.

Researchers are evaluating the safety, tolerability, and initial effects of two dosages of golexanolone compared to placebo in adults with Primary Biliary Cholangitis PBC who experience significant fatigue and cognitive symptoms. This phase 1b2 randomized, double-blind, placebo-controlled study focuses on patients with non-cirrhotic or mild cirrhotic PBC Child-Pugh class A who are on stable standard care medication. The study aims to understand how golexanolone affects fatigue, daytime sleepiness, cognitive function, and overall quality of life. The study has two parts Part A assesses safety, tolerability, and pharmacokinetics of golexanolone 40 mg taken twice daily for 5 days. Part B evaluates safety, tolerability, and effects of two dose levels 40 mg and 80 mg, twice daily compared to placebo over 28 days. Participants receive soft gelatin capsules orally twice daily during these periods. The study uses a parallel design with randomized allocation and quadruple masking to compare golexanolone doses and placebo. Participants will be monitored from enrollment through 5 days in Part A and 28 days in Part B, with assessments including adverse event tracking, quality of life questionnaires PBC-40, EQ-5D-3L, sleepiness scales, cognitive tests, and investigator impressions of treatment effect. Pharmacokinetic sampling occurs on days 1, 14, and 28 in Part B. Safety and tolerability are closely observed, with the total participation lasting up to 28 days depending on the part enrolled.

This observational study focuses on adults with symptomatic internal hemorrhoidal disease who are scheduled to undergo laser hemorrhoidoplasty. It aims to evaluate clinical outcomes including postoperative pain, complications, and patient satisfaction. The study also explores how hemorrhoid stage, main symptoms, and surgical details relate to recovery and overall results. The research is conducted at the General Surgery Clinic of Sanliurfa Education and Research Hospital. Participants will receive laser hemorrhoidoplasty, a minimally invasive procedure that uses laser energy to coagulate and shrink hemorrhoidal tissue without cutting. The study collects data during routine clinical care without adding any extra treatments. Surgical details such as laser wavelength and energy used, number of treated hemorrhoids, and any additional procedures will be recorded. Participants will be followed through their normal recovery process with assessments including pain scores at 6 hours, 24 hours, and 1 week after surgery. Researchers will track analgesic use, hospital stay length, time to resume daily activities, and any complications occurring within 30 days. Patient satisfaction and symptom recurrence will be evaluated up to 3 and 6 months after surgery. The study plans to clarify laser hemorrhoidoplastys clinical role and help guide patient selection.

Researchers are comparing two types of nerve blocks used for pain control after inguinal hernia surgery the anterior iliac block and the ilioinguinaliliohypogastric block. The study aims to see which technique provides longer-lasting pain relief and better patient satisfaction. This comparison is important because effective pain management can improve comfort and reduce the need for opioid medications after surgery. Participants will receive either the anterior iliac block or the ilioinguinaliliohypogastric block after their hernia surgery. These nerve blocks are given to help manage pain at the surgical site. The study is randomized and double-blinded, meaning neither the patients nor the researchers know which block is being given to ensure unbiased results. During the study, pain levels will be measured using a Numeric Rating Scale NRS at multiple times after surgery 0, 1, 3, 6, 12, and 24 hours. Researchers will also assess patient satisfaction and track how much additional pain medication is needed. The study plans to start in April 2026 and follow participants until September 2026, focusing on safety and effectiveness of these pain relief methods.

Researchers are evaluating the diagnostic accuracy of computed tomography CT reporting and the Appendicitis Inflammatory Response AIR score in adults suspected of having acute appendicitis who undergo appendectomy. The study aims to measure how often appendectomies are performed unnecessarily, based on final pathology results. It also examines how well the AIR score, CT findings, and surgical severity grading agree with pathology, and explores these diagnostics across different patient groups. This prospective observational study includes adults 18 years and older who visit the emergency department with suspected appendicitis, receive a CT scan showing signs of appendicitis, and then have an appendectomy. No extra treatments or interventions apart from standard care are performed. Clinical, demographic, and diagnostic data including laboratory results, CT reports, and surgical findings are collected and analyzed. Participants will have their clinical data recorded, including symptom details, lab tests, and imaging results. Researchers will compare CT reports, AIR scores, and surgical grades to final pathology findings within 30 days after surgery. The main measurement is the rate of negative appendectomies. Data is collected confidentially, with no study procedures beyond routine care, and the study is expected to end by January 2027.

Researchers are evaluating how two types of regional anesthesia affect brain oxygen levels and carotid artery size during shoulder surgery. The study compares the use of an interscalene block alone versus a combination of interscalene block and superficial cervical plexus block. These nerve blocks are often used to manage pain in shoulder surgeries and the study aims to understand their effects on brain oxygenation, blood flow, and postoperative pain. Participants will receive one of two anesthesia approaches under ultrasound guidance after sedation with midazolam. The first group will get an interscalene brachial plexus block alone, and the second group will receive both interscalene and superficial cervical plexus blocks. Oxygen levels in both brain hemispheres and carotid artery diameter will be measured multiple times before, during, and after surgery using near-infrared spectroscopy and ultrasonography. During the study, patients will be monitored closely with repeated measurements of cerebral oxygen saturation and carotid artery size at specific time points including before block, during surgery in the beach chair position, and postoperatively while supine. Sensory block quality and pain levels will be assessed, with recording of the time to first postoperative pain and need for analgesics. The study also tracks opioid use up to 24 hours after surgery to evaluate pain management. Participants are involved from sedation through surgery and recovery with careful monitoring of their brain and vascular responses.